CV:ACST Acasti Pharma Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol ACST.

2.15 CAD
As of 10/18/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   94,333,872 CAD
Current dividend yield:   0.00%
CUSIP:    
ISIN:        CA00430K4028
Sedol:      

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy